Perhaps I can try to give a quick answer.
I can't really get into the internal deliberations of the task force. I can say that we did meet and discuss with the U.K. vaccine task force. We were quite interested in learning the lessons from other countries. On this issue of the U.K. experience and of domestic biomanufacturing, I said that my ministry did an extensive survey of the biomanufacturing capabilities in Canada. We did that with the support of expert consultants. This was very early last spring, in the early days of the pandemic.
To take the U.K. as an example, the U.K. had a number of very large contract manufacturing operators that were capable of quickly shifting to produce COVID vaccines. The U.K. had also started years before the pandemic, in fact in 2017, to launch a significant rebuilding strategy. For one of the big facilities they are building, which won't be ready until later this year, they launched the construction in 2019, a year before the pandemic hit.
As Minister Champagne said, the U.K. certainly pivoted and was able to do manufacturing domestically, but they were starting from a much higher base, including having facilities—